PMID: 16506355Mar 2, 2006Paper

Ranolazine, a novel agent for chronic stable angina

Pharmacotherapy
Sarah M Gaffney

Abstract

One of the first signs of ischemic heart disease may manifest as chronic stable angina, a mismatch between oxygen supply and demand. With more than approximately 16.5 million people each year having stable angina, development of new therapies to help control this disease state are warranted. Ranolazine, a novel agent exerting its effect through a partial fatty oxidase inhibitor, is one of the first new drugs in more than 20 years to be developed for chronic stable angina. Working through enzymatic modulation, instead of altering myocardial hemodynamics, ranolazine appears to be effective. An overview of chronic stable angina is provided, the American College of Cardiology-American Heart Association (ACC-AHA) current pharmacologic treatment guidelines are reviewed, and the mechanism of action of ranolazine is explored. Finally, the major clinical trials supporting its place in medical therapy are discussed. Additional clinical trials are under way to further elucidate ranolazine's exact role in the treatment of chronic stable angina. From results of the existing phase III clinical trials, however, the most beneficial potential role of ranolazine in the treatment algorithm of chronic stable angina appears to be as adjunctive ther...Continue Reading

References

Jan 21, 1997·Circulation·G D Lopaschuk, W C Stanley
Apr 29, 1998·General Pharmacology·J G McCormackA A Wolff
May 4, 2002·Heart Failure Reviews·Nandakumar SambandamMichael F Allard
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Bernard R ChaitmanUNKNOWN Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Peter Berger
Apr 16, 2004·European Heart Journal·Leong LeeMichael Frenneaux
Apr 20, 2004·Journal of the American College of Cardiology·Bernard R ChaitmanUNKNOWN MARISA Investigators
Apr 29, 2004·JAMA : the Journal of the American Medical Association·Justin S Hooper, Anthony J Busti
Apr 29, 2004·JAMA : the Journal of the American Medical Association·Christoph Pechlaner, Christian Wiedermann
Oct 12, 2004·Mayo Clinic Proceedings·Eric H YangAmir Lerman
Jan 27, 2005·The American Journal of Cardiology·Michel F RousseauAndrew A Wolff
Jun 14, 2005·Journal of Clinical Pharmacology·Hisham Abdallah, Markus Jerling

❮ Previous
Next ❯

Citations

Jul 6, 2006·Nature Reviews. Drug Discovery·Jonathan AbramsPeter Kirkpatrick
Jun 28, 2011·Nature Reviews. Drug Discovery·David C Swinney, Jason Anthony
Jan 22, 2011·Journal of Cardiovascular Medicine·Catherine NortonJaved Butler
Sep 1, 2006·Photomedicine and Laser Surgery
Mar 13, 2010·Expert Review of Cardiovascular Therapy·Thorsten Reffelmann, Robert A Kloner
Aug 25, 2012·Expert Opinion on Investigational Drugs·Stylianos Tzeis, George Andrikopoulos
Feb 14, 2007·Clinical Therapeutics·Judy W M Cheng
Nov 17, 2009·JACC. Cardiovascular Imaging·Rajesh VenkataramanAmi E Iskandrian
Nov 14, 2016·International Journal of Cardiology·Kinjal BanerjeeAnjan Gupta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.